TNF and inflammatory bowel disease: [2,3] Although biological therapies, such as anti-tumor necrosis factor (TNF-)α therapies, have been successfully introduced, up to 40% of patients with IBD are inadequate responders to primary anti-TNF-α treatment, and another 30% to 40% lose this response within 1 year of treatment [4,5].